| Gene symbol | CTAG1B | Synonyms | CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | cancer/testis antigen 1B | ||||
| GTO ID | GTC0141 |
| Trial ID | NCT01567891 |
| Disease | Ovarian Cancer |
| Altered gene | NY-ESO-1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | NY-ESO-1 TCR-T cells |
| HLA | HLA-A*02:01|HLA-A*02:05|HLA-A*02:06 |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer. |
| Year | 2012 |
| Country | United States |
| Company sponsor | Adaptimmune |
| Other ID(s) | ADP-0011-001|230612 |
| Cohort 1 | |||||||||||||||||
|
|||||||||||||||||